These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 18265425

  • 21. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?
    Smith RJ, Schwartz EJ.
    Math Biosci; 2008 Apr; 212(2):180-7. PubMed ID: 18359048
    [Abstract] [Full Text] [Related]

  • 22. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA.
    WHO/UNAIDS/IAVI International Expert Group.
    AIDS; 2007 Feb 19; 21(4):539-46. PubMed ID: 17301582
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Anti-HIV adaptive immunity: determinants for viral persistence.
    Yamamoto H, Matano T.
    Rev Med Virol; 2008 Feb 19; 18(5):293-303. PubMed ID: 18416450
    [Abstract] [Full Text] [Related]

  • 25. [Towards a vaccine for HIV infection: role of the gp41 envelope protein].
    Debre P, Costagliola D, Legrand R, Vieillard V.
    Bull Acad Natl Med; 2009 Jan 19; 193(1):127-36; discussion 137-8. PubMed ID: 19718985
    [Abstract] [Full Text] [Related]

  • 26. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location.
    Masopust D.
    J Intern Med; 2009 Jan 19; 265(1):125-37. PubMed ID: 19093965
    [Abstract] [Full Text] [Related]

  • 27. Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection.
    Brumme ZL, Tao I, Szeto S, Brumme CJ, Carlson JM, Chan D, Kadie C, Frahm N, Brander C, Walker B, Heckerman D, Harrigan PR.
    AIDS; 2008 Jul 11; 22(11):1277-86. PubMed ID: 18580606
    [Abstract] [Full Text] [Related]

  • 28. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
    Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Monini P, Magnani M, Garaci E.
    AIDS; 2008 Oct 18; 22(16):2207-9. PubMed ID: 18832884
    [Abstract] [Full Text] [Related]

  • 29. Modelling the impact of acute infection dynamics on the accumulation of HIV-1 mutations.
    Shiri T, Welte A.
    J Theor Biol; 2011 Jun 21; 279(1):44-54. PubMed ID: 21420419
    [Abstract] [Full Text] [Related]

  • 30. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J, Ngai N, Stone GW, Yue FY, Ostrowski MA.
    Vaccine; 2009 Aug 13; 27(37):5077-84. PubMed ID: 19573639
    [Abstract] [Full Text] [Related]

  • 31. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, Gurner D, Gardiner D, Basu S, Ho DD, Tsuji M.
    Vaccine; 2008 Mar 28; 26(15):1807-16. PubMed ID: 18329757
    [Abstract] [Full Text] [Related]

  • 32. The potential of heat shock protein-peptide complexes as a therapeutic HIV vaccine.
    Levey DL, Brander C, Srivastava PK.
    J HIV Ther; 2005 Sep 28; 10(3):56-9. PubMed ID: 16385973
    [Abstract] [Full Text] [Related]

  • 33. [Vaccinations of HIV-infected travelers].
    Couzigou C, Voyer C, Shaghaghi CK, Bourée P, Vittecoq D.
    Med Mal Infect; 2009 Jan 28; 39(1):21-8. PubMed ID: 18723304
    [Abstract] [Full Text] [Related]

  • 34. Elite control of HIV Infection: implications for vaccines and treatment.
    Walker BD.
    Top HIV Med; 2007 Jan 28; 15(4):134-6. PubMed ID: 17720999
    [Abstract] [Full Text] [Related]

  • 35. Multiple transmissions of a stable human leucocyte antigen-B27 cytotoxic T-cell-escape strain of HIV-1 in The Netherlands.
    Cornelissen M, Hoogland FM, Back NK, Jurriaans S, Zorgdrager F, Bakker M, Brinkman K, Prins M, van der Kuyl AC.
    AIDS; 2009 Jul 31; 23(12):1495-500. PubMed ID: 19487902
    [Abstract] [Full Text] [Related]

  • 36. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
    Cukalac T, Moffat JM, Venturi V, Davenport MP, Doherty PC, Turner SJ, Stambas J.
    Vaccine; 2009 Nov 12; 27(48):6755-61. PubMed ID: 19744584
    [Abstract] [Full Text] [Related]

  • 37. Mathematical study of a staged-progression HIV model with imperfect vaccine.
    Gumel AB, McCluskey CC, van den Driessche P.
    Bull Math Biol; 2006 Nov 12; 68(8):2105-28. PubMed ID: 16868850
    [Abstract] [Full Text] [Related]

  • 38. The impact of imperfect vaccines on the evolution of HIV virulence.
    Massad E, Coutinho FA, Burattini MN, Lopez LF, Struchiner CJ.
    Med Hypotheses; 2006 Nov 12; 66(5):907-11. PubMed ID: 16442745
    [Abstract] [Full Text] [Related]

  • 39. Murine models for HIV vaccination and challenge.
    Boberg A, Bråve A, Johansson S, Wahren B, Hinkula J, Rollman E.
    Expert Rev Vaccines; 2008 Feb 12; 7(1):117-30. PubMed ID: 18251698
    [Abstract] [Full Text] [Related]

  • 40. Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial.
    Cai T, Gilbert PB, Self SG.
    J Biopharm Stat; 2006 Feb 12; 16(4):517-38. PubMed ID: 16892911
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.